339 related articles for article (PubMed ID: 16154384)
1. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages.
Sun YX; Tsuboi K; Zhao LY; Okamoto Y; Lambert DM; Ueda N
Biochim Biophys Acta; 2005 Oct; 1736(3):211-20. PubMed ID: 16154384
[TBL] [Abstract][Full Text] [Related]
2. Predominant expression of lysosomal N-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies.
Tsuboi K; Zhao LY; Okamoto Y; Araki N; Ueno M; Sakamoto H; Ueda N
Biochim Biophys Acta; 2007 May; 1771(5):623-32. PubMed ID: 17462942
[TBL] [Abstract][Full Text] [Related]
3. N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
Alhouayek M; Bottemanne P; Makriyannis A; Muccioli GG
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 May; 1862(5):474-484. PubMed ID: 28065729
[TBL] [Abstract][Full Text] [Related]
4. The N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Tsuboi K; Takezaki N; Ueda N
Chem Biodivers; 2007 Aug; 4(8):1914-25. PubMed ID: 17712833
[TBL] [Abstract][Full Text] [Related]
5. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Ueda N; Tsuboi K; Uyama T
Prog Lipid Res; 2010 Oct; 49(4):299-315. PubMed ID: 20152858
[TBL] [Abstract][Full Text] [Related]
6. Expression and secretion of N-acylethanolamine-hydrolysing acid amidase in human prostate cancer cells.
Wang J; Zhao LY; Uyama T; Tsuboi K; Wu XX; Kakehi Y; Ueda N
J Biochem; 2008 Nov; 144(5):685-90. PubMed ID: 18806270
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase.
Tsuboi K; Sun YX; Okamoto Y; Araki N; Tonai T; Ueda N
J Biol Chem; 2005 Mar; 280(12):11082-92. PubMed ID: 15655246
[TBL] [Abstract][Full Text] [Related]
8. N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase.
Tsuboi K; Hilligsmann C; Vandevoorde S; Lambert DM; Ueda N
Biochem J; 2004 Apr; 379(Pt 1):99-106. PubMed ID: 14686878
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice.
Hoyer FF; Khoury M; Slomka H; Kebschull M; Lerner R; Lutz B; Schott H; Lütjohann D; Wojtalla A; Becker A; Zimmer A; Nickenig G
J Mol Cell Cardiol; 2014 Jan; 66():126-32. PubMed ID: 24286707
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
Gouveia-Figueira S; Karlsson J; Deplano A; Hashemian S; Svensson M; Fredriksson Sundbom M; Congiu C; Onnis V; Fowler CJ
PLoS One; 2015; 10(9):e0139212. PubMed ID: 26406890
[TBL] [Abstract][Full Text] [Related]
12. The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake.
Thors L; Alajakku K; Fowler CJ
Br J Pharmacol; 2007 Apr; 150(7):951-60. PubMed ID: 17325653
[TBL] [Abstract][Full Text] [Related]
13. Endogenous molecules stimulating N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Tai T; Tsuboi K; Uyama T; Masuda K; Cravatt BF; Houchi H; Ueda N
ACS Chem Neurosci; 2012 May; 3(5):379-85. PubMed ID: 22860206
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase.
Saturnino C; Petrosino S; Ligresti A; Palladino C; De Martino G; Bisogno T; Di Marzo V
Bioorg Med Chem Lett; 2010 Feb; 20(3):1210-3. PubMed ID: 20022504
[TBL] [Abstract][Full Text] [Related]
15. N-acylethanolamine hydrolyzing acid amidase inhibition: tools and potential therapeutic opportunities.
Bottemanne P; Muccioli GG; Alhouayek M
Drug Discov Today; 2018 Aug; 23(8):1520-1529. PubMed ID: 29567427
[TBL] [Abstract][Full Text] [Related]
16. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.
Alhouayek M; Bottemanne P; Subramanian KV; Lambert DM; Makriyannis A; Cani PD; Muccioli GG
FASEB J; 2015 Feb; 29(2):650-61. PubMed ID: 25384424
[TBL] [Abstract][Full Text] [Related]
17. Lipophilic amines as potent inhibitors of N-acylethanolamine-hydrolyzing acid amidase.
Yamano Y; Tsuboi K; Hozaki Y; Takahashi K; Jin XH; Ueda N; Wada A
Bioorg Med Chem; 2012 Jun; 20(11):3658-65. PubMed ID: 22542283
[TBL] [Abstract][Full Text] [Related]
18. A second N-acylethanolamine hydrolase in mammalian tissues.
Ueda N; Tsuboi K; Lambert DM
Neuropharmacology; 2005 Jun; 48(8):1079-85. PubMed ID: 15910884
[TBL] [Abstract][Full Text] [Related]
19. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
20. N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition, but Not Fatty Acid Amide Hydrolase Inhibition, Prevents the Development of Experimental Autoimmune Encephalomyelitis in Mice.
Bottemanne P; Guillemot-Legris O; Paquot A; Masquelier J; Malamas M; Makriyannis A; Alhouayek M; Muccioli GG
Neurotherapeutics; 2021 Jul; 18(3):1815-1833. PubMed ID: 34235639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
